C7240
Anti-phospho-c-Met (pTyr1230/pTyr1234/pTyr1235) antibody produced in rabbit
affinity isolated antibody, buffered aqueous glycerol solution
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Source biologique
rabbit
Niveau de qualité
Conjugué
unconjugated
Forme d'anticorps
affinity isolated antibody
Type de produit anticorps
primary antibodies
Clone
polyclonal
Forme
buffered aqueous glycerol solution
Espèces réactives
rat, human, mouse
Technique(s)
western blot: 1:1000 using using 293T kidney cells transiently transfected with human c-Met and stimulated with HGF
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Température de stockage
−20°C
Modification post-traductionnelle de la cible
phosphorylation (pTyr1230/pTyr1234/pTyr1235)
Informations sur le gène
human ... MET(4233)
mouse ... Met(17295)
rat ... Met(24553)
Description générale
MET, a gene for receptor tyrosine kinase, was first isolated in human osteosarcoma-derived cell line. Hepatocyte growth factor (HGF) has been identified as the natural ligand for the c-Met receptor protein. HGF-induced c-Met activation is tightly regulated in the cells. Activation of the c-Met receptor results in binding and/or phosphorylation of many intracellular signaling proteins including multiple adaptor proteins (e.g., Grb2, Shc, Cbl, Crk, cortactin, paxillin, and GAB1) and a variety of other signal transducers (e.g., PI 3-kinase, FAK, Src, ERK1, JNK1, PLCa, and STAT3). HGF/Met signalling is actively responsible stimulating tumor angiogenesis, tumor growth, hypoxia and metastasis. Met overexpression through persistent ligand stimulation has been reported in many epithelial and mesenchymal cancers. Overexpression of Met enables metastasis in lung cancers, mutations in MET gene sequence have been reported in papillary renal cell carcinoma, lung cancers, ovarian, prostate, cervical, gastric and head and neck cancers. Anti-phospho-c-Met recognises human and mouse c-Met phosphorylated on Tyr1230, Tyr1234 and Try1235. Cross reaction with rat is expected due to 100% homology.
Immunogène
synthetic phosphopeptide derived from the region of c-Met that contains tyrosines 1230, 1234 and 1235.
Application
Detection of phospho-c-Met by immunoblotting may be performed by using a working concentration of 0.11.0 μg/mL in 293T kidney cells, SP-1 mouse myeloma cells stimulated with HGF and A431 cells stimulated with EGF.
Forme physique
Solution in Dulbecco′s phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3, with 50% glycerol, 1.0 mg/mL BSA (IgG and protease free) and 0.05% sodium azide.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
10 - Combustible liquids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Équipement de protection individuelle
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Joseph Paul Eder et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(7), 2207-2214 (2009-03-26)
A wide variety of human malignancies exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the breast, liver, lung, ovary, kidney, and thyroid. Notably, activating mutations in c-Met have been positively identified in patients with a particular hereditary form
K A Furge et al.
Oncogene, 19(49), 5582-5589 (2000-12-15)
The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses. The ligand for Met is hepatocyte growth factor/scatter factor (HGF/SF) and while normal
Fabiola Cecchi et al.
European journal of cancer (Oxford, England : 1990), 46(7), 1260-1270 (2010-03-23)
Under normal conditions, hepatocyte growth factor (HGF)-induced Met tyrosine kinase (TK) activation is tightly regulated by paracrine ligand delivery, ligand activation at the target cell surface, and ligand activated receptor internalisation and degradation. Despite these controls, HGF/Met signalling contributes to
S Fan et al.
Molecular and cellular biology, 21(15), 4968-4984 (2001-07-05)
Hepatocyte growth factor (scatter factor) (HGF/SF) is a pleiotrophic mediator of epithelial cell motility, morphogenesis, angiogenesis, and tumorigenesis. HGF/SF protects cells against DNA damage by a pathway from its receptor c-Met to phosphatidylinositol 3-kinase (PI3K) to c-Akt, resulting in enhanced
P Longati et al.
Current drug targets, 2(1), 41-55 (2001-07-24)
Control of cell growth and differentiation occurs via extracellular signals known as growth factors. Growth factors are high affinity ligands for transmembrane receptors belonging to the family of receptor tyrosine kinases (RTKs). A number of genetic evidences have implicated RTKs
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique